Gunderson Dettmer Advises TScan Therapeutics on Initial Public Offering
Gunderson Dettmer advised client TScan Therapeutics, a biotechnology company developing immunotherapy treatments for cancer, on its initial public offering. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
The company announced the shares began trading on the Nasdaq Global Select Market on July 16, 2021 under the ticker symbol “TCRX.” Morgan Stanley, Jefferies, Cowen and Barclays acted as Joint Bookrunning Managers for the offering.
The Gunderson deal team was led by partners Tim Ehrlich, Jay Hachigian, Jeffery Vetter, James Hauser, and Brendan McCarthy, of counsel Keith Scherer, and associates Julie Mahoney, Georgios Pothoulakis, Brittany Nicely, Frances Sevilla-Sacasa, John Maciejewski, Max Noreng and Alexandra Noymer.